U.S. Hospitality Stock News

NYSEAM:OPTT
NYSEAM:OPTTElectrical

Does Ocean Power Technologies' (OPTT) Share Plan Shift Reveal a New Funding Playbook for Maritime Defense?

At its 2025 Annual Meeting of Stockholders held on January 27, 2026, Ocean Power Technologies elected Jim Thompson and Corliss J. Montesi to its board, with shareholders also considering proposals to increase share issuance limits and expand equity incentive plans supporting its intelligent maritime focus. This governance shift comes shortly after the company secured a U.S. homeland security contract, underscoring its push into defense-oriented intelligent maritime solutions spanning power,...
NYSE:LUV
NYSE:LUVAirlines

US Stock Market Today: S&P 500 Futures Fall As Higher Yields Pressure Tech

The Morning Bull - US Market Morning Update Friday, Jan, 30 2026 US stock futures are pointing lower this morning, with key contracts for the S&P 500 and Nasdaq-100 down around 0.8% to 1%, as investors absorb mixed global signals. Taiwan just posted Q4 2025 GDP growth of 12.68% year on year, a surge linked to AI related tech demand, which highlights how much of the current growth story leans on chips and electronics. At the same time, the US 10 year Treasury yield has pushed above 4.27% and...
NYSE:LEVI
NYSE:LEVILuxury

Levi Strauss (LEVI) Margin Expansion Reinforces Bullish Earnings Narrative

Levi Strauss (LEVI) closed out FY 2025 with fourth quarter revenue of US$1,765.8 million and basic EPS of US$0.41, setting the tone for a year in which trailing twelve month revenue reached US$6.3 billion and EPS came in at US$1.27. Over the last few quarters, the company has seen revenue move from US$1,443.1 million in Q3 FY 2024 to US$1,749.9 million in Q4 FY 2024 and then to US$1,765.8 million in Q4 FY 2025. Quarterly EPS shifted from US$0.06 to US$0.45 to US$0.41 over the same stretch,...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Viavi IRINS Aims To Counter Threats And Deepen Defense Exposure

Viavi Solutions (NasdaqGS:VIAV) announced the launch of the IRINS navigation platform through its Inertial Labs business. The new system is designed to counter spoofing and jamming threats targeting military and critical infrastructure operations. IRINS focuses on assured navigation and continuity of service in mission critical environments. For you as an investor, this launch highlights how Viavi Solutions is leaning into sectors where continuity and resilience are central requirements,...
NasdaqGS:UNIT
NasdaqGS:UNITTelecom

Is Uniti’s 8.625% 2032 Note Offering Reshaping the Investment Case for Uniti Group (UNIT)?

In January 2026, Uniti Group Inc. issued new fixed-income securities, including US$500,000,000 of 8.625% senior notes and US$1 billion of 8.625% senior unsecured notes due 2032 under Regulation S and Rule 144A, with attached guarantees. The completion of these large, guaranteed senior unsecured note offerings materially reshapes Uniti Group’s capital structure and future interest obligations. We’ll now examine how Uniti Group’s sizable 8.625% senior unsecured notes due 2032 may influence...
NasdaqGS:TRMK
NasdaqGS:TRMKBanks

Trustmark’s Record Earnings And Buyback Plan Underline Shareholder Return Focus

Trustmark (NasdaqGS:TRMK) has reported record full-year earnings, highlighting strong performance across core banking, mortgage banking, and wealth management. The company has raised its quarterly dividend, signaling confidence in its balance sheet and ongoing cash generation. Trustmark also approved a new $100 million stock repurchase program, adding another lever for returning capital to shareholders. At a recent share price of $42.32, Trustmark comes into this news with solid longer term...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals (CPRX)?

In recent days, Catalyst Pharmaceuticals has been highlighted for strong earnings and revenue growth, solid profitability, and a debt-free balance sheet, earning it a spot on an “Affordable Growth” screen. At the same time, upbeat analyst views and collaborations with BioMarin Pharmaceutical and Endo Ventures have reinforced Catalyst’s rare-disease focus as a key differentiator in the biotechnology space. We’ll now examine how Catalyst’s combination of robust financial health and...
NYSE:LAZ
NYSE:LAZCapital Markets

Lazard (LAZ) Margin Compression To 7.6% Tests Bullish Earnings Growth Narratives

Lazard (LAZ) has capped FY 2025 with fourth quarter revenue of US$906.7 million, basic EPS of US$0.50 and net income excluding extra items of US$49.9 million, setting a clear marker for how the year wrapped up. The firm has seen quarterly revenue move from US$811.4 million in Q4 2024 to US$906.7 million in Q4 2025, while Q4 EPS shifted from US$0.89 to US$0.50 over the same stretch, giving investors a mixed read on top line scale and per share profitability as they weigh what softer margins...